Physician profile
Maxine Baum
NPI 1568689594
$10,085.07
in general payments reported to CMS, 2019-2025
26 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $995 · 2021: $1,486 · 2022: $1,469 · 2023: $1,666 · 2024: $1,180 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,200.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,127.11 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,680.79 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,650.21 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,132.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.75 | 2019-2024 | Spiriva Respimat |
| Optinose US, INC. | $574.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $477.91 | 2019-2025 | |
| Amgen INC. | $476.21 | 2022-2025 | Tezspire |
| Kaleo, INC. | $258.06 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $225.38 | 2019-2025 | Xolair |
| Pfizer INC. | $211.51 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $130.97 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $89.84 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $77.42 | 2022-2025 | Ryaltris |
| Takeda Pharmaceuticals U.S.A., INC. | $49.40 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $45.12 | 2023-2024 | Opzelura |
| Biocryst US Sales Co., LLC | $34.62 | 2025 | Orladeyo |
| Eyevance Pharmaceuticals LLC | $31.05 | 2020-2021 | |
| Cycle Pharmaceuticals INC | $27.06 | 2025 | Sajazir |
| Csl Behring | $25.00 | 2019 | |
| Leo Pharma INC. | $22.79 | 2022 | |
| Mylan Specialty L.P. | $22.64 | 2020 | |
| Abbvie INC. | $21.86 | 2022 | |
| Horizon Therapeutics Plc | $21.10 | 2019 | |
| Merck Sharp & Dohme LLC | $18.39 | 2021 | |
| Circassia INC. | $17.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxine Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.